Roivant Sciences Ltd. $ROIV Stock: 71 West Capital Partners Increases Position

71 West Capital Partners lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 573.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 290,735 shares of the company's stock after acquiring an additional 247,571 shares during the period. 71 West Capital Partners' holdings in Roivant Sciences were worth $10,632,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. AlphaCore Capital LLC purchased a new position in Roivant Sciences during the third quarter valued at $365,000. Retirement Systems of Alabama boosted its holdings in shares of Roivant Sciences by 19.8% during the 3rd quarter. Retirement Systems of Alabama now owns 558,777 shares of the company's stock valued at $20,434,000 after purchasing an additional 92,427 shares during the last quarter. Ethic Inc. boosted its holdings in shares of Roivant Sciences by 36.9% during the 3rd quarter. Ethic Inc. now owns 18,226 shares of the company's stock valued at $667,000 after purchasing an additional 4,914 shares during the last quarter. Pictet Asset Management Holding SA grew its position in shares of Roivant Sciences by 20.3% during the third quarter. Pictet Asset Management Holding SA now owns 4,173,123 shares of the company's stock valued at $152,597,000 after purchasing an additional 704,783 shares in the last quarter. Finally, AlphaCentric Advisors LLC boosted its stake in Roivant Sciences by 4.5% during the third quarter. AlphaCentric Advisors LLC now owns 50,535 shares of the company's stock valued at $1,848,000 after buying an additional 2,180 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Up 4.6%

NASDAQ:ROIV opened at $40.67 on Tuesday. The business has a 50 day simple moving average of $36.81 and a 200-day simple moving average of $31.89. Roivant Sciences Ltd. has a 1 year low of $19.79 and a 1 year high of $42.50.

Insider Transactions at Roivant Sciences

In related news, insider Mayukh Sukhatme sold 284,707 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75. Following the sale, the insider owned 18,630,739 shares of the company's stock, valued at $675,364,288.75. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Eric Venker sold 200,000 shares of the business's stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $35.11, for a total transaction of $7,022,000.00. Following the completion of the transaction, the chief executive officer owned 1,399,154 shares of the company's stock, valued at $49,124,296.94. This represents a 12.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,022,688 shares of company stock worth $73,438,636 over the last 90 days. Insiders own 8.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Sanford C. Bernstein raised Roivant Sciences to a "strong-buy" rating in a research note on Wednesday, July 29th. Citigroup upped their price objective on Roivant Sciences from $46.00 to $56.00 and gave the stock a "buy" rating in a report on Wednesday, October 28th. Jefferies Financial Group increased their target price on Roivant Sciences from $42.00 to $52.00 and gave the company a "buy" rating in a research report on Tuesday, September 8th. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 24th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.55.

More Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: For Q2 FY2027, Roivant reported a loss of $0.19 per share, narrower than analyst estimates of roughly $0.37–$0.41, and revenue of $35.12 million versus an estimated $4.14 million. The earnings and revenue beats are likely supportive of ROIV. Zacks earnings report
• Positive Sentiment: A report highlighted that the LISRAYA launch beat expectations, offering a potential commercial contribution alongside the quarterly results. LISRAYA launch report
• Positive Sentiment: Immunovant reported that IMVT-1402 met the primary endpoint in a potentially registrational difficult-to-treat rheumatoid arthritis trial, with strong exploratory response rates. As a Roivant-affiliated company, this clinical progress may bolster the broader pipeline outlook. Immunovant corporate update
• Negative Sentiment: Roivant’s CEO reportedly sold $7.26 million of company stock. Insider sales can weigh on sentiment, although a sale alone does not establish the executive’s view of the company’s prospects. CEO stock sale report
• Neutral Sentiment: Immunovant said it is unlikely to advance IMVT-1402 further for Sjögren’s disease beyond its ongoing Phase 2 trial, while planning discussions with the FDA on the rheumatoid arthritis program. That tempers the otherwise encouraging clinical update. Immunovant corporate update

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases.

Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Roivant operates internationally, with activities spanning the United States and other markets.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.